ILS-920，≥98% (HPLC)

Synonym: (3S,6R,7E,9R,10R,12R,14S,15S,18R,19E,21S,23S,26R,27R,34aS)-3,4,9,10,13,14,15,16,18,21,22,23,24,25,26,27,32,33,34,34a-eicosahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-16-phenyl-23,27-epoxy-15,18-ethenopyrido[2,1-r][1,16,2,19]dioxadiazacyclohentriacontine-1,5,11,28,29(6H,12H,31H)-pentone

 

5, 25 mg in glass bottle

 

ILS-920 is a rapamycin derivative with reduced immunosuppressive activity and enhanced neuroprotective activities including efficacy in vivo stroke model. ILS-920 predominantly binds to FKBP52 with a 972-fold higher selectivity for FKBP52 vs. FKBP12 than that of rapamycin, and also binds to the β-subunit of L-type voltage dependent Ca²⁺ channels. This dual functionality may contribute to the compound′s efficacy in stroke models.

 

ILS-920 是一种雷帕霉素衍生物，具有降低的免疫抑制活性和增强的神经保护活性，包括在体内中风模型中的功效。 ILS-920 主要与 FKBP52 结合，对 FKBP52 与 FKBP12 的选择性比雷帕霉素高 972 倍，并且还结合 L 型电压依赖性 Ca2+ 通道的 β-亚基。 这种双重功能可能有助于该化合物在中风模型中的功效。

 

This compound was developed by Pfizer for Immunology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

 

Sold for research purposes under agreement from Pfizer Inc.

Pfizer is a registered trademark of Pfizer, Inc.